People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Annexon, Inc. | — | Biotechnology | Series D+ | $278.5M | $2.8B | 2020 |
| Dermira, Inc. | — | Other Health Care | Series C | $113.0M | $22.9M | 2014 |
| Somaxon Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $6.0M | $185.8M | 2009 |
Thomas G. Wiggans at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas G. Wiggans on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David F Hale | 1 | 16 |
| Wende Hutton | 1 | 16 |
| EUGENE A. BAUER | 1 | 7 |
| Kurt Von Emster | 1 | 6 |
| Jake Nunn | 1 | 5 |
| Jesse I. Treu | 1 | 5 |
| Richard W. Pascoe | 1 | 4 |
| Jake R. Nunn | 1 | 4 |
| David E. Cohen | 1 | 4 |
| Stacie Weninger | 1 | 4 |
| WILLIAM D. YOUNG | 1 | 4 |
| Muneer A. Satter | 1 | 3 |
| Erle T. Mast | 1 | 3 |
| Thomas Wiggans | 1 | 3 |
| Matthew K. Fust | 1 | 3 |
| Eugene Bauer | 1 | 3 |
| Kurt C. Wheeler | 1 | 3 |
| Fred B. Craves | 1 | 3 |
| Mark D. McDade | 1 | 3 |
| Andrew L. Guggenhime | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.